ORIGINAL RESEARCH article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1636171

This article is part of the Research TopicAntibody-Mediated Thrombotic DiseaseView all 3 articles

Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome

Provisionally accepted
Oscar  Cabrera-MaranteOscar Cabrera-Marante1Daniel  PleguezueloDaniel Pleguezuelo1Sara  GarcinuñoSara Garcinuño1Laura  NaranjoLaura Naranjo1Raquel  Diaz-SimonRaquel Diaz-Simon2Francisco Javier  Gil EtayoFrancisco Javier Gil Etayo3Denis  ZafraDenis Zafra4Fernando  Lozano MorilloFernando Lozano Morillo5Luis  MorillasLuis Morillas5Magdalena  AbadMagdalena Abad6Olga  VillarOlga Villar6Antonio  Martínez-SalioAntonio Martínez-Salio7Tito  Leoncio Lizarraga- HurtadoTito Leoncio Lizarraga- Hurtado8Estela  Paz ArtalEstela Paz Artal1Antonio  SerranoAntonio Serrano1*Manuel  SerranoManuel Serrano1
  • 1Servicio de Inmunología, Hospital Universitario 12 de Octubre, Madrid, Spain
  • 2Hospital 12 de Octubre Servicio de Medicina Interna, Madrid, Spain
  • 3Hospital Universitario de Salamanca, Salamanca, Spain
  • 4Hospital Universitario 12 de Octubre servicio de Hematologia y Hemoterapia, Madrid, Spain
  • 5Hospital Universitario 12 de Octubre servicio de Reumatologia, Madrid, Spain
  • 6Hospital Universitario 12 de Octubre Servicio de Obstetricia y Ginecologia, Madrid, Spain
  • 7Hospital Universitario 12 de Octubre Servicio de Neurologia, Madrid, Spain
  • 8Hospital Universitario 12 de Octubre Servicio de Medicina Ocupacional, Madrid, Spain

The final, formatted version of the article will be published soon.

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombotic symptoms (venous, arterial or small vessels) and/or gestational morbidity in patients carrying antiphospholipid antibodies (aPL). Criteria aPL are anti cardiolipin, anti Beta 2 glycoprotein I (aB2GPI) of IgG or IgM isotypes and lupus anticoagulant (LA). However, there are aPL associated with APS events but not included in the criteria (extra-criteria). The aim of this study is to evaluate the prevalence and association of criteria and extra-criteria aPL with APS clinical events. Methods: 838 patients with clinical manifestations of APS were studied. 715 presented vascular manifestations and 130 obstetric morbidity. We measured levels of criteria aPL and the extra-criteria aPL determined were anti-phosphatidylserine/prothrombin (aPS/PT) of IgG and IgM isotypes and aB2GPI IgA.Classic-aPL, aPS/PT and aB2GPI IgA positivity showed a significant and independent association with thrombosis (OR: 2.40, 2.36, and 2.53 respectively). IgA aB2GP1 was the only aPL significantly associated to the 5 types of thrombotic events (venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction and arterial thrombosis). Regarding obstetric APS, the most relevant antibodies were classic-aPL of IgM isotype (OR:36.04) and aPS/PT of both isotypes (OR:4.4). The other aPL studied did not show association in multivariate analysis.The degree of clinical association for each group of aPL was different depending on the form of presentation (vascular or obstetric) and the presence or absence of autoimmune diseases. Moreover, a fair level of agreement between LA and aPS/PT positivity was found, therefore, aPS/PT should not be referred as a surrogate marker of LA.

Keywords: Anti-phospholipid antibodies, Anti-phosphatidylserine/prothrombin, lupus anticoagulant, Anti-phospholipid syndrome, thrombosis. (Min.5-Max. 8)

Received: 27 May 2025; Accepted: 25 Jun 2025.

Copyright: © 2025 Cabrera-Marante, Pleguezuelo, Garcinuño, Naranjo, Diaz-Simon, Gil Etayo, Zafra, Lozano Morillo, Morillas, Abad, Villar, Martínez-Salio, Lizarraga- Hurtado, Paz Artal, Serrano and Serrano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Antonio Serrano, Servicio de Inmunología, Hospital Universitario 12 de Octubre, Madrid, Spain

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.